Protagonist Therapeutics (PTGX) reported Q4 earnings Friday of $1.98 per diluted share, up from $0.44 a year earlier.
License and collaboration revenue for the quarter ended Dec. 31 was $170.6 million, compared with $60 million a year earlier.
The company said it expects its cash, cash equivalents and marketable securities of $559.2 million as of Dec. 31 to provide cash runway through the end of 2028.
Shares of the company were up more than 4% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.